Results-DO7 and 1801 gave the most specific and reliable results on immunohistochemisry and western blot analysis. Using these two antibodies, a noncompetitive sandwich type ELISA system was developed to analyse p53 quantitatively. Analysis of the breast cancer series showed a good correlation between immunohistochemistry and the ELISAtumours were generally positive using both techniques. Discrepancies were noted however: some cancers were immunohistochemically negative but ELISA positive. One explanation for this may be that the ELISA is more sensitive than immunohistochemistry.
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Conclusion-The p53 ELISA system is a non-competitive double monoclonal antibody sandwich method, using D07 and 1801 which have been shown to be highly specific for p53 protein by immunohistochemistry and western blot analysis. The lower threshold of the assay is 0.1 ng/nd analyte in an enriched recombinant p53 preparation. As p53 is now regarded as a protein associated with prognosis in breast and other cancers, the assay may have clinical applications. The prediction of likely outcome in cancer would permit allocation of patients to appropriate aggressive therapeutic regimens in instances where prognosis is poor; and conversely, patients with good prognosis could be spared dangerous and debilitating treatment. Mutations of the tumour suppressor gene p53 can result in dysfunction, with accumulation of the inactive/mutated protein which increases genomic instability leading to the expression and progression of the metastatic phenotype.' Accumulation of p53 has been shown in several different cancers.2" In breast cancer, we and others have shown that accumulation of p53 is associated with poor clinical prognosis.57 Although p53 overexpression can be detected immunohistochemically, only a qualitative estimation can be made. It has, however, been proposed that quantitative analysis of p53 protein concentrations in cancer will provide additional objective prognostic information.8 Several groups have described non-competitive sandwich type immunological based assay systems, using monoclonal/polyclonal antibody combinations, for quantitative analysis of p53 in tumour cytosol.9-' Using immunohistochemistry, we have recently reported that assessment of p53 status in breast cancer tissue sections is critically dependent upon the antibodies used for screening, and influences the significance of the prognostic data generated.5 Similarly, the choice of antibodies to be applied in quantitative p53 assays may exert a notable effect on the final estimate of tumour p53 concentrations. Selection of the most appropriate antibodies will assure the specificity and reproducability of the data on which subsequent assessments of patient prognosis may be based.
Methods

TUMOUR TISSUE
Samples of mammary carcinoma tissue were collected at surgery. The tumour was dissected free of superfluous tissue and representative samples processed for the production of frozen sections and cytosols.
CYTOSOL PREPARATION p53 was quantified in cytosol extracts prepared for routine estimation of oestrogen/ progesterone receptor analysis. Frozen tumour tissue (approximately 5 mm2) was powdered using a micro-dismembranator and resuspended in 1 ml HEPES/EDTA buffer (20 mM HEPES, 1.5 mM EDTA, pH 7.4) containing protease inhibitors: aprotinin (2 jg/ml), leupeptin (2 jg/ml), phenylmethylsulphonyl fluoride (PMSF) (50 jig/ml), and pepstatin (1 jg/ ml). Further disruption was achieved using sonication. Owing to the heat lability of the proteins to be assayed, the samples were maintained on ice throughout the process. The tissue/cell lysate was clarified by ultracentrifugation, 50 000 x g at 4°C for 40 minutes. Cytosol fractions were collected, and stored at -70°C prior to analysis for p53. Samples were analysed within two weeks of preparation. ESTIMATION antibodies at 0.5 jg/ml, or rabbit anti-serum CM1 at a dilution of 1 in 1000 were applied and incubated with sections for one hour at room temperature. Binding of p53 antibody was detected using biotinylated goat antimouse or goat anti-rabbit polyclonal antiserum and streptavidin/biotinylayed horseradish peroxidase complex (Dako, High Wycombe, UK). Sections were developed with 3,3-diaminobenzidine tetrahydrochloride (Sigma, Poole, Dorset, UK) in Tris buffered saline (TBS) containing 0.3% hydrogen peroxide, counterstained with Meyer's haematoxylin, dehydrated stepwise in ethanol, cleared in xylene, and mounted. Tumours were scored according to the proportion of cells showing nuclear reactivity: -, no reactivity; +, <25% reactivity; ++, 25-50% reactivity; and +++, >50% reactivity.
WESTERN BLOT ANALYSIS
Specificity of the p53 antibodies was assessed using western blot analysis against a cell lysate of the breast adenocarcinoma cell line MDA-MB-231. Cells mechanically harvested from confluent 250 ml tissue culture flasks were washed three times with PBS and lysed in 1.5 ml ice cold Laemmli buffer (0.125 M Tris, 4% SDS, 40% glycerol,1 % bromophenol blue, and 5% mercaptoethanol, pH6.8). The lysate was held on ice, sonnicated using a single five second burst, and stored at -70°C until required. Samples of lysate were fractionated by discontinuous SDS-polyacrylamide gel electrophoresis, using a 10% T, 2.6% C, polyacrylamide gel. Proteins were transferred onto nitrocellulose membrane using a semi-dry electroblotting system. Blots were probed with p53 antibodies D07, 1801, BP53.12, 421, each at 0.5 jig/ml and with CM1 at dilutions of 1 in 1000 and 1 in 2000. Reacted p53 antibodies were detected using alkaline phosphatase conjugated goat anti-mouse immunoglobulin or goat anti-rabbit immunoglobulin polyclonal anti-sera. Blots were developed with 0.1 mg/ml nitroblue tetrazolium/0.15 mg/ml BCIP (5-bromo-4-chloro-3-indolyl phosphate), in development buffer (0.1 M Tris buffer, 0.1 M NaCl and 50 mM MgCl2, pH 9).
SELECTION OF p53 ANTIBODIES FOR ELISA DEVELOPMENT p53 antibodies for the development of the ELISA were selected on the basis of their performance in immunohistochemistry, for optimum assignment of p53 status, and their specificity for p53 in western blot analysis. Using these criteria, monoclonal antibodies 1801 and D07 were selected for use in assay development.
PREPARATION OF BIOTINYLATED Do7
Monoclonal antibody D07 was purified from hybridoma culture supernatant by absorption with protein A (Sigma). Antibody removed by three washes with PBS (this buffer was used for all subsequent washing steps), and the wells incubated for one hour at 37°C with 200 jl 5% BSA in PBS, to block non-specific immunoreactivity. Wells were then washed once and incubated for three hours at 370C with 50 tld standard recombinant p53 protein, tumour cytosol at 2 mg/ml, 1 mg/ml, 0.5 mg/ ml, and 2.5 mg/ml, or patient serum diluted 1 in 10 and 1 in 100. In each instance, 2% BSA in PBS was used as the diluent. After washing three times, the wells were next incubated for two hours at 37°C with 50 gl biotinylated D07 diluted 1 in 10 in 2% BSA in PBS (this buffer was used for all subsequent antibody dilutions). The wells were washed again three times and then incubated for one hour at 37°C with 50 gl sheep anti-biotin polyclonal antiserum (The Binding Site, Birmingham, UK) diluted 1 in 1000. Specificity of this reagent was assured by extensive pre-absorption with mouse IgGagarose. After washing three times, the wells were incubated for one hour at 37°C with 50 gl horseradish peroxidase conjugated donkey anti-sheep immunoglobulin anti-serum (Stratech Scientific Ltd, Luton, UK) diluted 1 in 4000. The wells were washed a final four times and developed with 50 gl 3,3' 5,5'-tetramethylbenzidine substrate. The reaction was stopped with 0.2 M sulphuric acid and results recorded at 250 nm using a Titertek multi-scan plate reader. The assay was standardised using an enriched preparation of recombinant p53 protein (kindly supplied by Professor D Lane). Test absorbance values were corrected against control values derived from wells processed in the absence of biotinylated D07. p53 concentrations were calculated with reference to the linear range of standard recombinant p53 titration curves. Cytosol p53 values were expressed as p53 ng/ mg total cytosol protein, and serum values as p53 ng/ml serum.
Results
IMMUNOHISTOCHEMISTRY
Using a series of breast carcinomas, we assessed the immunohistochemical performance of p53 antibodies for the assignment of tumour p53 status. Each antibody was assessed on consecutive sections cut from each tumour sample. For immunohistochemistry, cryopreserved tissue was used in preference to formalin fixed, paraffin wax embedded tissue as the results generated would best reflect the performance of the antibodies in ELISA for the analysis of p53 in cancer cytosol. Positive staining with any of the monoclonal antibodies tested was restricted to the nucleus, and was consistent with the nuclear localisation of p53. In comparison, however, CM1 commonly exhibited reactivity within the cell cytoplasm which was independent of nuclear staining, suggesting reactivity with cellular antigens in addition to p53. On this basis, cancers assessed for p53 using CM1 were scored p53 positive only if nuclear staining was apparent. Table 1 shows the percentage of cancers scored as p53 positive using each of the antibodies tested. A higher percentage of cancers were scored p53 positive with monoclonal antibodies D07 and 1801 than any of the other antibodies tested, indicating that D07 and 1801 identify most p53 positive can- D07 binding was achieved using sheep antibiotin and horseradish peroxidase conjugated donkey anti-sheep immunoglobulin polyclonal anti-sera (fig 2) . A typical calibration curve for the p53 assay using an enriched preparation of standard recombinant p53 is shown in fig 3. The detection limit, the concentration of p53 which could be distinguished from the zero value with 95% confidence, was 0.1 ng/ml of the enriched p53 protein. antibodies 1801 and D07, in comparison with 421 and BP53.12, and that polyclonal antibody CM1 performs poorly. These findings are similar to those reported in routinely processed tissue.5 In addition to the immunohistochemical assessment of p53 antibodies, we have also analysed their specificity for p53 by western blotting. CM1 was again found to perform poorly, exhibiting only weak reactivity with p53 and stronger reactivity with other cellular antigens. In comparison, monoclonal antibodies 1801, D07 and BP53.12, exhibit specificity for a single protein with molecular weight indicative of p53. From analysis of these data, we suggest that quantitative immunoassay systems for p53 using CM1 may not produce consistently specific and reproducible results. As monoclonal antibodies D07 and 1801 were preferentially selected for both their detection of p53 in immunohistochemistry and their specificity for p53 in western blot analysis, we suggest that the quantitative immunoassay system we describe has advantages over other systems for analysis of tumour p53 concentrations.
D07 and 1801 bind epitope regions located at the N-terminus of the p53 molecule: 1801 recognises an epitope mapping between amino acid residues 32-7912 and D07 within the region defined by amino acids 20-25.'3 Both regions are distant from the central portion of the p53 molecule which is most commonly affected by point mutations.'4 We, therefore, suggest that these epitope regions will be structurally conserved in a high proportion of cancers, and, thus, it is expected that in most cancers p53 protein concentrations can be measured using this antibody combination. No competition of p53 binding was observed between the two antibodies when using solid phase 1801 and D07 as the p53 detector. To accommodate the reduction in amplification accompanying the use of a monoclonal antibody as p53 detector in comparison with a polyclonal anti-serum-for example, CM 1, we labelled D07 with biotin and used sheep antibiotin anti-sera and horseradish peroxidase conjugated donkey anti-sheep immunoglobulin anti-sera. This approach permitted the detection of 0.1 ng/ml of p53 in an enriched recombinant p53 preparation. This is less than that described by other assays using CM1.9 10 We are, however, confident in suggesting that the analyte measured in our system is p53.
The ELISA system was used to assess quantitative p53 values in a small series of breast cancers, and the results compared with immunohistochemical staining of frozen sections from representative samples of the same cancer tissue, using antibodies 1801 and D07. All cancers with positive immunohistochemical status were similarly positive in ELISA, with p53 values ranging from 1 to 14.9 ng/mg. In general, high immunohistochemically p53 positive cancers had corresponding high quantitative p53 values. About 38% of the series scored immunohistochemically negative had positive values in ELISA, with values ranging from 0.3 to 2 ng/mg. Owing to the high specificity of the antibodies used in the ELISA, we suggest that these cancers are indeed p53 positive, but the levels expressed are below the threshold value for immunohistochemical detection. Alternatively, the variation between cytosol and immunohistochemical results may simply reflect heterogeneity within a tumour, suggesting that more relevant cancer p53 data will be obtained from assessment of samples taken from several different sites of the primary cancer. In line with previous findings, p53 was not detected in the serum samples."
In conclusion, we suggest that our method is a precise and sensitive immunologically based system for the quantitative analysis of p53 protein. Whether the precise estimation of p53 will provide more significant prognostic data will be assessed by the analysis of a larger series of cancer cytosols.
